secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001437749-22-027003
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q3 net loss $3.97M; cash jumps to $34.7M; Phase 2 trials advance
-----------------------------------------------------------------------

- Net loss $3.97M ($0.17/sh) for Q3 2022 vs $1.95M ($0.31) in Q3 2021; 9-month net loss $8.64M.
- Cash $34.7M at Sep 30, 2022 vs $11.4M at Dec 31, 2021; raised $27.7M from stock/warrant sales and $7.6M from warrant exercises.
- Phase 2 COVID vaccine GEO-CM04S1 advancing; Lancet Microbe data show robust neutralizing antibodies and T cells; expanding sites.
- Gedeptin Phase 1/2 for head and neck cancer expands to Emory and Thomas Jefferson; FDA orphan grant funded.
- Secured rights to NIH-MVA for monkeypox/smallpox; began preclinical studies for pan-coronavirus and MUC1 immunotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774922027003/0001437749-22-027003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774922027003/govx20221109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-027003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer